Open Access

Prognostic assessment of patients who receive radiotherapy for bone metastases from breast cancer

  • Authors:
    • Kenji Makita
    • Hiromitsu Kanzaki
    • Yasushi Hamamoto
    • Kei Nagasaki
    • Masaaki Kataoka
    • Teruhito Kido
    • Shozo Ohsumi
  • View Affiliations

  • Published online on: March 28, 2023     https://doi.org/10.3892/ol.2023.13775
  • Article Number: 188
  • Copyright: © Makita et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

For prognostic assessment in women who receive radiotherapy (RT) for bone metastases (BMs) from breast cancer (BC), prognostic factors specific for BMs from BC were investigated in the present study. The prognostic assessment was performed by retrospectively reviewing 143 women who received first‑time RT for BMs from BC between January 2007 and June 2018. The median follow‑up time and median overall survival (OS) time from the first‑time RT for BMs were 22 and 18 months, respectively. In the multivariate analysis, nuclear grade 3 (NG 3) [hazard ratio, 2.18; 95% confidence interval (CI), 1.34‑3.53], brain metastases (hazard ratio, 1.96; 95% CI, 1.01‑3.81), liver metastases (hazard ratio, 1.75; 95% CI, 1.17‑2.63), performance status (PS) (hazard ratio, 1.63; 95% CI, 1.10‑2.41) and previous systemic therapy (hazard ratio, 1.58; 95% CI, 1.03‑2.42) were significant factors for OS, whereas age, hormone‑receptor/human epidermal growth factor receptor 2 status, number of BMs and synchronous lung metastases were not significant factors. When points according to risk levels [unfavorable points (UFPs)] were assigned to each risk factor (1.5 points for NG 3 and brain metastases; and 1 point for PS ≥2, previous systemic therapy and liver metastases), the median OS times of patients with a total number of UFPs ≤1 (n=45), 1.5‑3 (n=55) and ≥3.5 (n=43) were 36, 17 and 6 months, respectively. Overall, in patients who received first‑time RT for BMs from BC, NG 3, brain/liver metastases, poor PS and previous systemic therapy were unfavorable prognostic factors. Comprehensive prognostic assessment using these factors seemed to be useful for the prediction of prognoses in patients with BMs from BC.
View Figures
View References

Related Articles

Journal Cover

May-2023
Volume 25 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Makita K, Kanzaki H, Hamamoto Y, Nagasaki K, Kataoka M, Kido T and Ohsumi S: Prognostic assessment of patients who receive radiotherapy for bone metastases from breast cancer. Oncol Lett 25: 188, 2023.
APA
Makita, K., Kanzaki, H., Hamamoto, Y., Nagasaki, K., Kataoka, M., Kido, T., & Ohsumi, S. (2023). Prognostic assessment of patients who receive radiotherapy for bone metastases from breast cancer. Oncology Letters, 25, 188. https://doi.org/10.3892/ol.2023.13775
MLA
Makita, K., Kanzaki, H., Hamamoto, Y., Nagasaki, K., Kataoka, M., Kido, T., Ohsumi, S."Prognostic assessment of patients who receive radiotherapy for bone metastases from breast cancer". Oncology Letters 25.5 (2023): 188.
Chicago
Makita, K., Kanzaki, H., Hamamoto, Y., Nagasaki, K., Kataoka, M., Kido, T., Ohsumi, S."Prognostic assessment of patients who receive radiotherapy for bone metastases from breast cancer". Oncology Letters 25, no. 5 (2023): 188. https://doi.org/10.3892/ol.2023.13775